KeyNeurotek AG to Start European Phase II Trial in Traumatic Brain Injury (TBI)
KeyNeurotek AG announced the start of a European Phase II trial of KN 38-7271 in traumatic brain injury (TBI) patients. The multi-center study of the cannabinoid receptor agonist will start in 12 clinics in Europe, including Germany and comprise more than 100 patients. The goal of the study is to demonstrate favorable tolerability and medical efficacy.
Traumatic brain injuries caused for example by accidents at work or at home, result in complex and often life threatening injuries of the brain, which at present cannot be treated pharmacologically. The drug candidate KN 38-7276 has been exclusively inlicensed by KeyNeurotek from Bayer Healthcare AG (Leverkusen, Germany) in 2005. KN 38-7271 is a novel cannabinoid receptor agonist activating both CB1 and CB2 cannabinoid receptors, thereby working via a dual mechanism of action: It has a lasting positive effect on the natural protection mechanisms of the very sensitive nerve cells and it also prevents the excessive inflammatory reactions common in brain injury.
Results of the Phase II study are expected in the first half of 2008.
Other news from the department research and development
